# Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage

Study · id `cardio:ct-nct06504576` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06504576](<https://clinicaltrials.gov/study/NCT06504576>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06504576

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06504576. Randomized; no masking; primary purpose treatment. Start 2025-06-16 (actual); primary completion 2027-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06504576, source copy `cardio:ctgov-nct06504576-2026-03-09`, retrieved 2026-10-31)
- Started: 2025-06-16 (actual) (ClinicalTrials.gov record NCT06504576, source copy `cardio:ctgov-nct06504576-2026-03-09`, retrieved 2026-10-31)
- Primary completion: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT06504576, source copy `cardio:ctgov-nct06504576-2026-03-09`, retrieved 2026-10-31)
- Completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT06504576, source copy `cardio:ctgov-nct06504576-2026-03-09`, retrieved 2026-10-31)
- Countries: Taiwan (ClinicalTrials.gov record NCT06504576, source copy `cardio:ctgov-nct06504576-2026-03-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06504576-2026-03-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage
- Acronym: EPOCH
- Condition: ICH - Intracerebral Hemorrhage
- Intervention (Drug): Pletaal 100mg/tab
- Intervention (Procedure): Conventional internal medicine treatment
- Lead sponsor: National Taiwan University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as the lead sponsor: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)

## Provenance

Content hash: 263580eaa347853415298fc30b1e10f29fcb19175c4dfe40756415364a97c3e5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
